PASADENA, Calif., April 1, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, today announced that insitro, a leading machine learning-powered drug discovery and development company, has executed an early renewal for a 6-year lease extension through August 31, 2034 for 143,188 RSF at 279 East Grand Avenue on the Alexandria C ...

Kelvin Cheng/iStock Editorial via Getty Images Article Thesis Alexandria Real Estate Equities, Inc. (NYSE:ARE) is a quality real estate investment trust that trades at an undemanding valuation while delivering compelling business growth and offering a solid income yield. At current prices, the REIT is an attractive income and value play. Overview Alexandria Real Estate Equities is oftentimes categorized as an office real estate investment trust, but the company isn't comparable to the likes of Boston Pr ...

TheaDesign Valuation has been forgotten in this market. REIT stocks have suffered from fear as continued problems in office cast a gloom over commercial real estate. Office is now only 3% of the REIT index, yet it has taken down AFFO multiples across the sector. High quality REITs are now trading at multiples that should be reserved for junky companies. There are 72 REITs trading below 15X AFFO and the majority of these are steadily growing earnings. We believe forward returns on these REITs will be wel ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a ...

Core Insights - Alexandria Real Estate Equities, Inc. (ARE) has secured a 10-year lease extension with Takeda Pharmaceutical for 222,925 rentable square feet at Kendall Square, ensuring long-term rental revenue stability [1] - The lease extension reflects Takeda's commitment to the Alexandria Center and highlights the importance of Alexandria's Labspace infrastructure in supporting innovative life science companies [1][2] - Alexandria has expanded its footprint in the Cambridge submarket to over 5.4 million rentable square feet across three mega campuses, positioning itself to meet the needs of leading life science firms [2] Group 1: Lease and Financial Details - The lease extension with Takeda will run through March 31, 2040, providing steady rental income for Alexandria [1] - Alexandria sold a 60% stake in the 75/125 Binney Street property for $438 million in 2019, achieving a cash capitalization rate of 4.3% and $202.2 million in excess of book value [3] - As of December 31, 2023, investment-grade or publicly traded large-cap tenants accounted for 52% of Alexandria's annual rental revenues, with a weighted average remaining lease term of 7.4 years [4] Group 2: Sustainability and Tenant Base - Alexandria and Takeda will collaborate on sustainability initiatives to enhance the building's environmental performance, focusing on occupant health, energy efficiency, and water usage reduction [3] - Alexandria serves a diverse tenant base, including multinational pharmaceutical companies and biotechnology firms, which supports its stable revenue stream [4] - The top 20 tenants of Alexandria have a weighted average remaining lease term of 9.6 years, indicating strong demand for its premium assets [4]

PASADENA, Calif., Feb. 28, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that the company will conduct a conference call and audio webcast on Tuesday, April 23, 2024, at 3:00 p.m. Eastern Time (ET), in conjunction with the release of its first quarter 2024 operating and financial results. Alexandria will release its operating and financial results after the market closes on Monday, April 22, 2024. To participate in this conference call, dial (833) 366-1125 (U.S.) or ...

Mental Health Crisis and Industry Response - The mental health crisis in the US is a significant public health challenge, with over 1 in 5 American adults living with a mental illness and over 50,000 suicides in 2023, including 6,000 veterans annually [1] - Untreated mental illness represents an economic burden of over $300 billion annually, with the true costs being even higher for affected individuals, families, and society [1] - The life science industry is showing renewed interest in developing medicines for mental health disorders, with recent advancements including the first FDA-approved oral treatment for postpartum depression by Biogen and Sage Therapeutics [1] Alexandria's Initiatives and Partnerships - Alexandria is convening its second Alexandria Summit on Mental Health in Washington, DC, to advance the development of novel psychiatric therapies and address unmet needs [1] - The company has partnered with Verily to create OneFifteen, a full continuum of care model for addiction treatment, which has treated over 7,500 patients since its opening in 2019 [3] - Alexandria has collaborated with the Navy SEAL Foundation since 2010, supporting specialized mental health programs for Naval Special Warfare personnel and veterans, including the establishment of the Warrior Fitness Program West Coast facility in San Diego [4] Biomarker Development and Public-Private Partnerships - The Alexandria Summit on Mental Health will feature a panel on creating a public-private partnership for biomarkers for depression, aiming to develop a data-driven and personalized framework for guiding patients to effective therapies [2] - Alexandria has formed a dedicated working group consisting of academics, innovators, non-profits, payors, providers, and biopharmaceutical executives to advance biomarker development and clinical trials [2] Alexandria's Market Position and Real Estate Portfolio - Alexandria Real Estate Equities, Inc is a leading life science REIT with a total market capitalization of $33 1 billion and an asset base of 73 5 million SF in North America as of December 31, 2023 [5] - The company operates 42 0 million RSF of operating properties, with 5 5 million RSF under construction and 23 9 million SF of future development projects [5] - Alexandria's life science mega campuses are located in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle [5]

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend y ...

Core Viewpoint - The S&P 500 Index has gained 6% in 2023, making it challenging to find value investments, but opportunities still exist, particularly in the REIT sector [2] - Alexandria Real Estate Equities, Inc. (ARE) is highlighted as a valuable investment opportunity due to its strong fundamentals and attractive valuation [2][4] Company Fundamentals - ARE's current dividend yield is 4.3%, with a 68% FFO payout ratio, which is below the 90% threshold preferred by rating agencies for REITs [3][4] - The company has a low debt-to-capital ratio of 29%, significantly below the 60% benchmark, and holds a BBB+ credit rating with a positive outlook from S&P [4] - The risk of a dividend cut during an average recession is estimated at 0.5%, increasing to 2% in a severe recession [4] Valuation and Growth Potential - ARE's shares are currently priced at $119, representing a 36% discount to a potential fair value of $187 based on historical P/FFO ratios and dividend yields [5] - Projected total returns over the next decade could reach 14.2% annually, significantly outperforming the S&P's expected 10% annual return [5] Recent Financial Performance - For Q4 2023, ARE reported total revenues of $757.2 million, a 13% increase year-over-year, exceeding analyst expectations by $5.8 million [6][8] - The FFO per share for Q4 was $2.28, reflecting a 6.5% year-over-year growth, although it slightly missed analyst consensus [9] - The company anticipates a midpoint FFO per share of $9.47 for 2024, indicating a 5.6% growth rate over 2023 [9] Dividend Growth Outlook - ARE's quarterly dividend has compounded by 30.9% over the past five years, with a current rate of $1.27, suggesting potential for continued growth [10] - If the dividend is raised to $1.30 in June, the projected payout ratio would be 54.3%, allowing for sustained dividend growth in line with FFO growth [10] Market Position - ARE is positioned as a leader in the life sciences REIT sector, with strong fundamentals and growth prospects, making it an attractive investment choice [12]

digicomphoto/iStock via Getty Images Dear readers, Alexandria Real Estate Equities (NYSE:ARE) is a blue-chip REIT focused on leasing exclusively to life science tenants in biotech and big pharma. The REIT has generated impressive shareholder returns since going public in 1997 and continues to deliver growth year after year with a 10-year FFO per share CAGR of 7.4%. Last year, the stock price plummeted on fears that life science is not that different from office and may experience occupancy issues. I address ...